Cytosorbents Corp (CTSO) Given Average Recommendation of “Buy” by Brokerages

Cytosorbents Corp (NASDAQ:CTSO) has been assigned a consensus rating of “Buy” from the six ratings firms that are presently covering the company, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $10.65.

Several research analysts have recently commented on CTSO shares. Maxim Group set a $12.00 price objective on Cytosorbents and gave the stock a “buy” rating in a report on Monday, January 8th. HC Wainwright restated a “buy” rating and set a $13.00 price target on shares of Cytosorbents in a report on Tuesday, November 21st. ValuEngine downgraded Cytosorbents from a “hold” rating to a “sell” rating in a report on Friday, December 15th. Finally, B. Riley set a $11.00 price target on Cytosorbents and gave the company a “buy” rating in a report on Friday, December 22nd.

In other Cytosorbents news, COO Vincent Capponi sold 4,000 shares of the company’s stock in a transaction that occurred on Monday, November 27th. The stock was sold at an average price of $7.00, for a total transaction of $28,000.00. Following the transaction, the chief operating officer now owns 271,062 shares in the company, valued at approximately $1,897,434. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CFO Kathleen P. Bloch sold 12,400 shares of the company’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $7.75, for a total value of $96,100.00. Following the transaction, the chief financial officer now owns 241,038 shares in the company, valued at approximately $1,868,044.50. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 48,800 shares of company stock worth $360,620. 5.60% of the stock is owned by company insiders.

Several hedge funds have recently bought and sold shares of CTSO. PNC Financial Services Group Inc. grew its holdings in shares of Cytosorbents by 145.2% during the 2nd quarter. PNC Financial Services Group Inc. now owns 38,000 shares of the medical research company’s stock worth $163,000 after acquiring an additional 22,500 shares during the period. Fortaleza Asset Management Inc. grew its holdings in shares of Cytosorbents by 81.6% during the 3rd quarter. Fortaleza Asset Management Inc. now owns 23,375 shares of the medical research company’s stock worth $145,000 after acquiring an additional 10,500 shares during the period. Wealthcare Advisory Partners LLC purchased a new position in shares of Cytosorbents during the 3rd quarter worth approximately $365,000. Skylands Capital LLC grew its holdings in shares of Cytosorbents by 45.1% during the 4th quarter. Skylands Capital LLC now owns 725,608 shares of the medical research company’s stock worth $4,716,000 after acquiring an additional 225,558 shares during the period. Finally, Wells Fargo & Company MN grew its holdings in shares of Cytosorbents by 182.3% during the 4th quarter. Wells Fargo & Company MN now owns 20,929 shares of the medical research company’s stock worth $136,000 after acquiring an additional 13,515 shares during the period. Hedge funds and other institutional investors own 9.53% of the company’s stock.

Cytosorbents (CTSO) opened at $7.40 on Wednesday. The company has a market capitalization of $212.32, a PE ratio of -19.47 and a beta of -0.18. The company has a quick ratio of 3.17, a current ratio of 3.36 and a debt-to-equity ratio of 0.73. Cytosorbents has a twelve month low of $3.30 and a twelve month high of $7.90.

TRADEMARK VIOLATION NOTICE: This piece of content was posted by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was illegally copied and republished in violation of international copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/14/cytosorbents-corp-ctso-given-average-recommendation-of-buy-by-brokerages.html.

About Cytosorbents

CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product, CytoSorb, which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company’s purification technologies are based on biocompatible, porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption.

Analyst Recommendations for Cytosorbents (NASDAQ:CTSO)

Receive News & Ratings for Cytosorbents Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytosorbents and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply